title: Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
abstract: Enzyme replacement therapy (ERT) with recombinant human (rh) acid α-glucosidase (GAA) has prolonged the survival of patients. However, the paucity of cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle, where it is needed to take up rhGAA, correlated with a poor response to ERT by muscle in Pompe disease. Clenbuterol, a selective β2 receptor agonist, enhanced the CI-MPR expression in striated muscle through Igf-1 mediated muscle hypertrophy, which correlated with increased CI-MPR (also the Igf-2 receptor) expression. In this study we have evaluated 4 new drugs in GAA knockout (KO) mice in combination with an adeno-associated virus (AAV) vector encoding human GAA, 3 alternative β2 agonists and dehydroepiandrosterone (DHEA). Mice were injected with AAV2/9-CBhGAA (1E+11 vector particles) at a dose that was not effective at clearing glycogen storage from the heart. Heart GAA activity was significantly increased by either salmeterol (p<0.01) or DHEA (p<0.05), in comparison with untreated mice. Furthermore, glycogen content was reduced in the heart by treatment with DHEA (p<0.001), salmeterol (p<0.05), formoterol (p<0.01), or clenbuterol (p<0.01) in combination with the AAV vector, in comparison with untreated GAA-KO mice. Wirehang testing revealed that salmeterol and the AAV vector significantly increased performance, in comparison with the AAV vector alone (p<0.001). Similarly, salmeterol with the vector increased performance significantly more than any of the other drugs. The most effective individual drugs had no significant effect in absence of vector, in comparison with untreated mice. Thus, salmeterol should be further developed as adjunctive therapy in combination with either ERT or gene therapy for Pompe disease.
authors.affiliation: Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, United States.
authors.forename: Sang-Oh
authors.initials: SO
authors.lastname: Han
authors.affiliation: Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, United States.
authors.forename: Songtao
authors.initials: S
authors.lastname: Li
authors.affiliation: Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, United States.
authors.forename: Dwight D
authors.initials: DD
authors.lastname: Koeberl
mesh_terms: D000818:Animals; D002976:Clenbuterol / Q000008:administration & dosage; D003687:Dehydroepiandrosterone / Q000008:administration & dosage; D000229:Dependovirus / Q000235:genetics; D004195:Disease Models, Animal; D056947:Enzyme Replacement Therapy; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage; D006003:Glycogen / Q000378:metabolism; D006009:Glycogen Storage Disease Type II / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D009206:Myocardium / Q000378:metabolism*; D000068299:Salmeterol Xinafoate / Q000008:administration & dosage*; D000520:alpha-Glucosidases / Q000235:genetics* / Q000378:metabolism*
chemical_list: D003687:Dehydroepiandrosterone; D000068299:Salmeterol Xinafoate; D006003:Glycogen; C509951:GAA protein, human; D000520:alpha-Glucosidases; D002976:Clenbuterol
keywords: Adeno-associated virus vector; Enzyme replacement therapy; Glycogen storage disease; Mannose-6-phosphate receptor; Pompe disease